Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | G6PD | P11413 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12643383 | 0.82 | RIPK1 (0.53) | RIPK1IDO1AGXTKDM4EALDH1A1 | |
| SCHEMBL6128132 | 0.81 | KDM4E (0.61) | KDM4EALDH1A1L3MBTL1MEN1POLB | |
| SCHEMBL12074780 | 0.81 | SLC6A4 (0.49) | KDM4EALDH1A1L3MBTL1MEN1POLB | |
| SCHEMBL27675073 | 0.80 | RIPK1 (0.48) | RIPK1IDO1AGXTKDM4EALDH1A1 | |
| SCHEMBL321645 | 0.79 | ALDH1A1 (0.54) | RIPK1KDM4EALDH1A1L3MBTL1MEN1 | |
| SCHEMBL13159521 | 0.79 | ADRA2B (0.44) | KDM4EALDH1A1L3MBTL1MEN1POLB | |
| SCHEMBL19445318 | 0.79 | SLC6A4 (0.58) | KDM4EALDH1A1L3MBTL1MEN1POLB | |
| SCHEMBL21419342 | 0.79 | PYCR1 (0.63) | KDM4EALDH1A1L3MBTL1MEN1POLB | |
| SCHEMBL16370307 | 0.79 | SLC6A2 (0.59) | KDM4EALDH1A1L3MBTL1MEN1POLB | |
| SCHEMBL1343896 | 0.79 | SLC6A4 (0.44) | KDM4EALDH1A1L3MBTL1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3904339-A1 | ALKYLAMINOPROLINE DERIVATIVES AS ALFA-2-DELTA-1 BLOCKERS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2021-11-03 | — | — | EP | disclosed |
| WO-2019215426-A1 | PROCESS FOR FORMING A CARBON-CARBON BOND | THE UNIVERSITY OF MANCHESTER (GB) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019215427-A1 | PROCESS FOR FORMING A CARBON-CARBON BOND | THE UNIVERSITY OF MANCHESTER (GB) | 2019-11-14 | — | — | WO | disclosed |
| WO-2011016501-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | 武田薬品工業株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-0401167-B1 | Process for the preparation of titanocenes with o,o'-difluoro ligands | CIBA GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| US-5075467-A | Reacting organotitanium halide with lithium amide | CIBA-GEIGY CORPORATION (US) | 1991-12-24 | — | — | US | disclosed |
| EP-0401167-A2 | Process for the preparation of titanocenes with o,o'-difluoro ligands | CIBA-GEIGY AG (CH) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | CX3CR1, CCL5, CCRL2 | RIPK1 1026/4885IDO1 490/4885AGXT 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.